Results 71 to 80 of about 280,195 (357)

Epstein‐Barr Virus Expressed Long Non‐Coding RNA (lncBARTs) Regulate EBV Latent Genome Replication

open access: yesAdvanced Science, EarlyView.
EBV produces abundant level of lncBARTs, which are essential for maintaining viral genome replication in EBV‐associated cancers. LncBARTs interact with a complex comprising BRD4, CTCF and viral protein EBNA1 at EBV oriP region. This interaction tethers oriP to host chromosomes, facilitating EBV episome replication.
Jiayan Liu   +12 more
wiley   +1 more source

T-Cell/Histiocyte Rich Large B-Cell Lymphoma –A Case Series with Review of Literature [PDF]

open access: yesNational Journal of Laboratory Medicine, 2017
T-Cell/Histiocyte Rich Large B-Cell Lymphoma (THRLBCL) is a rare variant of Diffuse Large B Cell Lymphoma (DLBCL). This entity differs from the classical DLBCL in the morphology as well as immunohistochemical expression of various CD markers.
Priavadhana Rajan Prasaad   +1 more
doaj   +1 more source

Spectrum of malignancies among the population of adults living with HIV infection in China: A nationwide follow-up study, 2008-2011. [PDF]

open access: yes, 2019
BackgroundAlthough increasingly studied in high-income countries, there is a paucity of data from the Chinese population on the patterns of cancer among people living with HIV (PLHIV).MethodsWe conducted a nationwide follow-up study using routinely ...
Detels, Roger   +7 more
core   +2 more sources

Cancer Biology of GSPT1: Mechanisms and Targeted Therapy Opportunities of Molecular Glue Degraders

open access: yesAdvanced Science, EarlyView.
This review systemically summarizes the structure, expression, regulatory networks, and isoform‐specific signaling of GSPT1 in cancers. According to the integration of GSPT1 targeted therapies, current challenges of GSPT1 targeted therapies are further analyzed, and provide therapeutic opportunities for the application of GSPT1 degraders in precision ...
Qiqi Lin   +8 more
wiley   +1 more source

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

open access: yesAdvanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong   +6 more
wiley   +1 more source

Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2011
OBJECTIVE: To evaluate the use of high-dose sequential chemotherapy in a Brazilian population. METHODS: High-dose cyclophosphamide followed by autologous hematopoietic stem cell transplantation is an effective and feasible therapy for refractory/relapsed
Bruno Kosa Lino Duarte   +12 more
doaj   +1 more source

CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT The tumor necrosis factor (TNF)‐receptor superfamily 8 receptor CD30 molecule is expressed in all tumor cells of Hodgkin lymphoma and anaplastic large cell lymphoma but is only weakly expressed in a small subset of large lymphoid cells in normal peripheral lymphoid tissues.
Harald Stein, Brunangelo Falini
wiley   +1 more source

Primary non-hodgkin′s lymphoma of bone: Experience of a decade

open access: yesIndian Journal of Pathology and Microbiology, 2010
Objective: To study the prevalence and characterization of primary non Hodgkin′s lymphoma of bone in a major referral center of Pakistan. Methodology: All cases of primary non Hodgkin′s lymphoma of bone, diagnosed at a referral center in ...
Qureshi Asim   +3 more
doaj  

Safety and preliminary efficacy of vorinostat with R-EPOCH in high-risk HIV-associated non-Hodgkin\u27s lymphoma (AMC-075) [PDF]

open access: yes, 2018
We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma.
Aboulafia, David   +12 more
core   +2 more sources

Home - About - Disclaimer - Privacy